Eterna Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 8731 https://eternatx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Eterna Therapeutics Inc

Eterna Therapeutics Reports Financial Results for Fourth Quarter and Full Year 2022 and Recent Business Highlights - Mar 20th, 2023 8:10 pm
Insiders might want to re-evaluate their US$2.7m stock purchase as Eterna Therapeutics Inc. (NASDAQ:ERNA) drops to US$16m - Mar 16th, 2023 11:04 am
EXCLUSIVE: Lineage Cell Inks Exclusive Agreement For Novel Cell-Based Therapies With Potential In Neurology - Feb 22nd, 2023 2:46 pm
Eterna Therapeutics Enters Into Option and License Agreement with Lineage Cell Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications - Feb 22nd, 2023 1:00 pm
Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President - Jan 4th, 2023 1:30 pm
In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews Dr. Matt Angel, CEO Eterna Therapeutics - Dec 20th, 2022 1:05 pm
Eterna Therapeutics Announces Research Collaboration to Develop Advanced Gene-Edited iPS Cell Therapies - Nov 1st, 2022 12:30 pm
Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress - Oct 18th, 2022 12:30 pm
Eterna Therapeutics Completes Name Change, Acquires Option to License iPSC-Derived NK and T Cell Therapies from Exacis Biotherapeutics - Oct 17th, 2022 12:30 pm